Elo Mutual Pension Insurance Co Sells 949 Shares of Kenvue Inc. (NYSE:KVUE)

Elo Mutual Pension Insurance Co cut its stake in shares of Kenvue Inc. (NYSE:KVUE) by 0.5% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 198,390 shares of the company’s stock after selling 949 shares during the quarter. Elo Mutual Pension Insurance Co’s holdings in Kenvue were worth $4,236,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Grove Bank & Trust increased its holdings in Kenvue by 438.4% during the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock valued at $25,000 after purchasing an additional 947 shares in the last quarter. Geneos Wealth Management Inc. bought a new position in shares of Kenvue in the fourth quarter valued at about $29,000. SRS Capital Advisors Inc. lifted its position in Kenvue by 67.4% during the 4th quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company’s stock worth $30,000 after buying an additional 571 shares in the last quarter. Fortitude Family Office LLC grew its holdings in Kenvue by 106.6% during the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock worth $32,000 after acquiring an additional 777 shares during the last quarter. Finally, Versant Capital Management Inc increased its position in Kenvue by 300.8% in the 4th quarter. Versant Capital Management Inc now owns 1,920 shares of the company’s stock valued at $41,000 after acquiring an additional 1,441 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Up 0.5 %

Shares of NYSE:KVUE opened at $23.52 on Friday. The company has a 50 day moving average price of $22.27 and a two-hundred day moving average price of $22.46. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The company has a market capitalization of $44.95 billion, a PE ratio of 44.38, a PEG ratio of 2.62 and a beta of 1.25. Kenvue Inc. has a 52 week low of $17.67 and a 52 week high of $24.46.

Kenvue (NYSE:KVUE) last released its quarterly earnings data on Thursday, February 6th. The company reported $0.26 EPS for the quarter, meeting analysts’ consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th were given a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.49%. The ex-dividend date of this dividend was Wednesday, February 12th. Kenvue’s dividend payout ratio is currently 154.72%.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on KVUE shares. Barclays increased their price target on shares of Kenvue from $21.00 to $23.00 and gave the company an “equal weight” rating in a research note on Thursday. Canaccord Genuity Group lifted their target price on Kenvue from $24.00 to $29.00 and gave the company a “buy” rating in a research note on Wednesday, March 5th. Deutsche Bank Aktiengesellschaft downgraded Kenvue from a “buy” rating to a “hold” rating and dropped their target price for the stock from $25.00 to $24.00 in a research report on Thursday, December 12th. UBS Group lowered their price objective on Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a research report on Friday, February 7th. Finally, Evercore ISI initiated coverage on shares of Kenvue in a research report on Monday. They set an “in-line” rating and a $25.00 target price on the stock. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have given a buy rating to the company. According to MarketBeat.com, Kenvue currently has a consensus rating of “Hold” and an average price target of $24.00.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.